MedTech’s AI Boom Is Turning Specialist Law Firms Into Product Teams

AI is no longer on the fringes of health care but is becoming a part of the products that clinicians and patients use. Algorithms are analysing scans, tracking signals from wearable devices, aiding clinical decisions and streamlining aspects of healthcare administration. The industry is taking a further step with generative AI, enabling developers to build systems that create summaries, recommendations, and other outputs that are less predictable than those of traditional software.

That growth is transforming more than just MedTech engineering. It is changing the role of legal advisers. The need to hire experienced law firm support is greater when a business is designing an AI-powered medical device or digital health product than when it is near the end of the product development process. What engineers can build can be affected by regulation, cybersecurity, clinical claims, use of data and software updates.

The outcome is an atypical transition. Specialist law firms are increasingly seen not as outside advisers to call in when something goes wrong, but as extensions of product teams.

AI Is Becoming Too Important for MedTech Legal Teams to Arrive Late

The level of investment in digital health signals the pace of change in the market. In 2025, U.S. digital health startups secured about $14.2 billion across 482 deals, a 35% increase from $10.5 billion in 2024.

A significant portion of that was spent on artificial intelligence. In 2025, 50% of digital health funding deals were with AI-enabled companies, and 54% of the capital invested went to AI-enabled companies. This was even more noticeable earlier in the year, as AI-powered companies accounted for 62% of digital health venture funding in the U.S. during the first half of 2025.

That investment is yielding companies that are eager to quickly develop and launch products. Healthcare can’t run at the same pace as consumer software.

A social media company can launch a feature, see how people use it days later, and make changes. If an AI system is going to impact medical decisions, it might need validation, documentation and regulatory consideration before significant changes are made.

This puts a tension between software development culture and medical device regulation. More and more specialist lawyers are caught up in the middle of that tension.

The FDA Is Paying Much Closer Attention to Medical AI

The regulators are moving fast as well. In the U.S., the Food and Drug Administration (FDA) maintains a list of AI-powered medical devices approved for sale, and AI has been integrated into several fields of medicine, including radiology, cardiovascular medicine, and clinical monitoring.

The regulatory discussion has progressed to the next generation of technology. In August 2026, the FDA launched a public conversation on generative AI-powered medical devices. Issues being considered include risk assessment, pre-market assessment and post-market monitoring.

That’s important because generative AI raises regulatory issues that traditional medical software doesn’t necessarily raise. Traditional software typically yields a fairly predictable output for a defined input. Generative systems can produce new content and may behave differently across situations. That’s a basic validation question for MedTech companies.

How would a manufacturer prove that a system is safe for millions of possible interactions? How to deal with an updated underlying model? What are the appropriate ways to track unexpected outputs post-launch? That’s an engineering question, but it’s also a regulatory question.

Lawyers Are Entering the Development Cycle

This means that specialist legal advisers might be brought in much earlier in the product development process. AI MedTech team members might be software engineers, clinicians, machine-learning researchers, cybersecurity experts and regulatory experts. Attorneys increasingly need to grasp the impact of each group on the other.

Think about the training data that an algorithm is using. Engineers may be interested in whether the data set is sufficiently large to improve the model’s performance. Patients in the data set may be asked whether they are sufficiently diverse to represent the patients seen by the clinician. Attorneys may be considering at the same time whether the company has the proper rights to use the information, whether privacy requirements have been met, and whether contractual restrictions will affect future commercialization.

All three discussions impact the product. If legal issues with a data set are discovered only after a model has been developed, a company may find itself in a costly re-development scenario. Legal capabilities can thus be integrated into the development process earlier to become risk engineering rather than just compliance.

AI Updates Are Changing What ‘Finished’ Means

The product lifecycle for traditional medical equipment tends to be relatively well-defined. A manufacturer takes the steps to create the device, get the necessary regulatory clearance and make it available.

Software is different. AI models can potentially be continually enhanced. Developers might wish to retrain the systems with more data, tweak algorithms, plug weaknesses, or add new features.

This is a reality that regulators have had to address. The FDA has issued guidance on preplanned change-control procedures for AI-driven device software functions. It acknowledges that the manufacturer may make some changes to the product once it is in the market.

Moreover, this puts software development itself on the lawyer’s regulatory checklist for MedTech companies. Teams must know which changes were expected, which need further documentation, and which are sufficient to warrant new regulatory questions.

The legal team can’t just look at 1.0 and ‘poof!’

Cybersecurity Has Become a Product Requirement

Another factor driving lawyers’ steps toward developers is cybersecurity. Today’s medical technology is increasingly interconnected. Smartphones, hospital systems, cloud platforms and external databases can all be reached by devices.

Each connection creates another potential attack surface. In February 2026, the FDA released new guidance on cybersecurity for medical devices, including device design, labeling, and documentation submitted to the FDA in premarket applications for devices that present cybersecurity risks.

This further takes cybersecurity out of the IT realm. Development security decisions can impact regulatory submissions. Manufacturers may require vulnerability identification, software updates and risk management processes throughout the life of the device.

A MedTech company’s cybersecurity lawyer therefore should be aware of, and know well more than, what occurs following a data breach. Prior to the device being released, they can be part of software architecture, vendor contracts, vulnerability management and incident-response planning.

Investors Are Likely to Examine Regulatory Foundations More Closely

AI funding also means that sooner or later, legal rulings can impact company valuations.

During 2025, digital health investors made significantly larger investments. Despite a rise in total funding, the number of deals actually dropped from 509 in 2024 to 482 in 2025. The average deal size increased as a result to approximately $20.7 million to $29.3 million.

The influence of the large rounds has continued to grow, with 26 rounds valued above $100 million. If investors are putting that type of money to work, regulatory bases matter.

Diligence for an AI MedTech may involve assessing whether the company owns its IP or has lawful access to training data, whether it is in compliance with applicable privacy regulations, and whether it has properly evaluated the regulatory status of its products.

What may seem a fantastic technology in a demo may not seem so good if it takes years of regulatory change to commercialize.

This puts seasoned legal departments in a new position: to make companies more investable by minimizing unaddressed regulatory risks in product development.

Law Firms Need Technologists Too

The transition also puts strain on attorneys. If a firm treats AI as a black box, it can’t provide effective advice about medical AI.

Moreover, the legal landscape surrounding AI is evolving quickly, and attorneys must now grasp the intricacies of model coaching, cloud computing, software updates, APIs, cybersecurity vulnerabilities, and algorithmic efficiency.

They don’t have to be machine learning engineers. However, they do need a certain level of technical knowledge to recognize when an engineering decision raises a legal issue.

But that could mean specialist companies will assemble more multidisciplinary teams of legal counsel, former regulators, technical consultants and healthcare professionals. The lines between legal guidance, regulatory strategy and product consulting might be increasingly blurred.

The Best Legal Advice May Prevent Problems From Being Built

In the past, a business could create a product and then consult with attorneys on how to introduce it to the market. That sequence is now more perilous with AI.

Privacy issues can arise from data options. Regulatory classifications can change for features. Marketing language can impact intended use. Cybersecurity obligations can be established by software architecture. The regulatory status of an already authorized device may change as a result of model updates.

A number of these issues are more economical to solve in the development phase than in the post-release phase. Hence, specialist law firms are increasingly being integrated into product teams.

AI is not just creating new devices in the MedTech revolution. It’s developing products in which software engineering, clinical evidence, cybersecurity, data governance, and regulations are all linked.

As that complexity grows, the most valuable legal counsel may no longer be the counsel that can help a company to react to a problem.